Safety and Immunogenicity of DAPTACEL Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With DAPTACEL or Pentacel.
Phase of Trial: Phase III
Latest Information Update: 03 Apr 2014
At a glance
- Drugs DTaP vaccine (Primary)
- Indications Diphtheria; Pertussis; Tetanus
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Sanofi
- 11 May 2010 Actual patient numbers changed from 650 to 649 as reported by ClinicalTrials.gov.
- 24 Sep 2008 Primary endpoint identified as to provide information concerning the safety of DTaP vaccine as reported by ClinicalTrials.gov
- 24 Sep 2008 Actual patient number (650) added as reported by ClinicalTrials.gov.